查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1862583

免疫疗法市场依治疗方法、适应症、给药途径、最终用户和作用机制划分－2025-2032年全球预测

Immunotherapy Drugs Market by Therapy Type, Indication, Route Of Administration, End User, Mechanism Of Action - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，免疫疗法药物市场将成长至 5,138.2 亿美元，复合年增长率为 12.73%。

关键市场统计数据
基准年 2024 1969.6亿美元
预计年份：2025年 2225.9亿美元
预测年份 2032 5138.2亿美元
复合年增长率 (%) 12.73%

本报告首先对现代免疫疗法的现状进行了简要概述。报告阐明了研究范围、目标和分析方法，旨在检验科学进展、临床发展、监管动态和商业性趋势。报告确立了后续分析的观点，包括临床疗效趋势、生产技术变革、供应链考量、监管要点以及相关人员的采纳驱动因素。透过事先设定这些参数，报告引导读者了解将影响研究、临床应用、生产规模化和市场进入等策略决策的相互关联的主题。

调查方法，引言部分阐述如何综合运用专家访谈、临床资料库审查、监管文件分析、专利分析以及真实世界证据，建构一个连贯的证据基础。引言部分也概述了资料三角验证的假设以及评估技术成熟度和实施准备度的标准。因此，引言部分明确地将本报告定位为决策者将科学研究机会与实际操作能力和政策现实结合的实用工具。

免疫疗法的研究、生产、商业化和患者获取途径正经历着变革性的转变，这些转变正在重新定义临床模式和投资者的优先事项。

近年来，免疫疗法领域发生了翻天覆地的变化，重塑了研究重点、商业化路径以及患者接受治疗的方式。精准细胞工程技术的进步，例如新一代受体设计和同种异体移植平台，正在催生更广泛的治疗概念和即用型产品。同时，疫苗平台、溶瘤载体和免疫调节剂的突破性进展正在融合为多模态疗法，从而改变临床开发策略的设计方式以及我们与监管机构的沟通方式。这些科学变革也伴随着营运层面的变革：模组化生产、一次性技术和分散式生产模式正在重新定义生产力计画和成本结构。

此外，资金筹措模式和投资者关注点正从早期药物发现转向可扩展的生产流程和持续临床疗效的验证，这迫使企业建立策略联盟并调整其市场推广策略。患者获取药物的考量也在改变。随着医疗系统在将复杂治疗方法整合到标准治疗路径方面面临挑战，以及支付方要求采用按疗效付费的模式，这些趋势正在重新定义免疫疗法生命週期中的价值创造，并迫使相关人员重新思考临床设计、供应链韧性、报销策略和长期商业化计划。

2025年美国关税对免疫疗法供应链、生产製造、临床试验和病患取得的累积影响

美国关税将于2025年生效，其累积影响将对整个免疫疗法供应链、生产经济和临床运作造成复杂的压力。进口试剂、特殊耗材、细胞处理设备和某些中间生技药品的关税相关成本增加，将直接对製造商和合约研发生产机构（CDMO）的运作构成不利影响。由于先进治疗方法生产的许多环节仍然依赖全球采购，这些额外成本可能会促使企业进行策略性调整，例如重新评估供应商合约、提高垂直整合程度以及增加本地化生产以降低风险。因此，除了成本和监管方面的考虑外，地缘政治风险将在製造地的决策中发挥越来越重要的作用。

除了生产製造之外，关税还会透过增加进口套件、低温运输物流和外包检测服务的成本，影响临床试验营运的经济效益。这可能导致试验週期延长，因为申办方需要寻找替代供应商并重新审核其资格。支付方和医疗系统也可能面临上游成本压力，进而影响高成本治疗方法的筹资策略和实施路径。为此，行业相关人员可能会优先考虑具有韧性的筹资策略，实现供应链多元化，尽可能投资国内生产能力，并积极与采购和政策相关人员沟通，以寻求豁免和缓解措施。最终，关税不会改变免疫疗法的科学潜力，但会重塑营运重点，并要求在生产、临床和商业等各个环节进行战术性调整。

针对治疗方法方式、适应症群、给药途径、最终用户以及临床和商业规划机制，提供可操作的细分洞察

深入理解市场区隔对于将研发策略与临床需求和商业化路径相匹配至关重要。在考虑治疗方法类型时，市场涵盖细胞疗法、癌症疫苗、查核点抑制剂、细胞激素和溶瘤病毒疗法。在细胞疗法领域，CAR-T疗法、NK细胞疗法和TCR-T疗法等亚类尤其重要，因为每种疗法在生产、监管和给药方面都面临着独特的挑战。癌症疫苗分为树突细胞疫苗、DNA疫苗和胜肽疫苗，它们在抗原选择、佐剂需求和给药方法方面存在差异。查核点抑制剂包括CTLA-4抑制剂、PD-1抑制剂和PD-L1抑制剂，每种抑制剂都有其自身的疗效和毒性特征，进而影响联合治疗策略。细胞激素疗法（例如集落刺激因子、干扰素和白细胞介素）作为免疫反应的调节剂和联合治疗的组成部分，继续发挥重要作用。溶瘤病毒疗法（包括基于腺病毒、疱疹病毒和呼肠孤病毒的平台）在载体设计、生产控制措施和免疫分析方面有其独特的考虑因素。

从适应症角度来看，将癌症细分为血液系统恶性肿瘤、乳癌、肺癌和黑色素瘤，可以揭示不同的临床路径和应用趋势。血液系统癌症亚型，如急性淋巴性白血病、急性骨髓性白血病、慢性淋巴性白血病和淋巴瘤，需要量身订做的细胞疗法和免疫调节策略。乳癌根据荷尔蒙受体阳性或三阴性进行分类，这反映了需要采用不同的生物标记主导策略和联合治疗。肺癌分为非小细胞肺癌和小细胞肺癌，会影响标靶选择和试验设计。同时，黑色素瘤的不同类型，例如皮肤黑色素瘤和葡萄膜黑色素瘤，表现出不同的免疫反应性。给药途径（肿瘤内、静脉注射、皮下）的选择直接影响供应链需求、临床基础设施和以病人为中心的照护模式。最终用户，例如医院、肿瘤诊所和专科治疗中心，会根据自身设施容量、临床医生经验和报销体系的不同，以不同的速度采用治疗方法。此外，作用机制——分为主动免疫疗法、联合治疗和被动免疫疗法——是策略优先排序的核心。主动疗法，例如癌症疫苗和溶瘤病毒疗法，着重于诱导内源性免疫反应；而被动疗法，例如过继性细胞疗法、查核点抑制剂和单株抗体，则依赖外源性效应因子的递送或抑制免疫抑制路径。总而言之，这些细分观点指南优先研发路径、临床试验设计和客製化商业化策略的製定，这些策略既体现了科学的细微差别，也反映了医疗服务的实际情况。

重点区域的采用趋势、基础设施发展、监管环境和市场进入的区域性洞察

区域趋势正在影响全球范围内的疗法采纳路径、基础设施准备、监管参与以及市场进入策略。在美洲，我们看到先进治疗方法的进展日益加速，尤其是在那些融合了学术领导、生产製造专长和支付者合作的卓越中心。这些生态系在支持快速临床转化的同时，也凸显了将高度复杂的治疗方法整合到常规诊疗路径中，以及与支付方协商基于价值的合作安排等切实可行策略的必要性。

在欧洲、中东和非洲地区，监管协调工作、国家健保体係以及多元化的医疗服务体系造就了广泛的应用环境。细胞和基因疗法的生产能力建设以及本地临床专业知识在不同地区差异显着，因此需要量身定制的打入市场策略、区域生产伙伴关係以及灵活的定价方法。在亚太地区，生物技术的快速投资、不断扩大的临床试验活动以及国内生产能力的扩张正在推动区域创新，即便监管路径日趋成熟。在所有地区，基础设施建设的进展，包括符合GMP标准的设施、低温运输物流和专业临床中心，将是决定应用速度的关键因素，相关人员需要将区域策略与当地的监管和医保实际情况相协调，以优化患者的治疗机会。

对管道配置、策略合作伙伴关係、製造能力、监管地位和商业化路径竞争考察

免疫疗法领域的竞争格局呈现出多元化的特点，参与者包括成熟的製药公司、生物技术创新者、专业契约製造和学术联盟。拥有差异化平台、将专有生物学见解与可扩展生产优势相结合的公司处于主导地位，而那些致力于产生可靠临床证据并衡量真实世界疗效的机构则与支付方和临床医生建立了长期互信的合作关係。策略合作、授权授权和有针对性的收购仍然是加速获取互补能力（例如载体生产、细胞处理自动化和伴随诊断）的关键手段。

随着主要企业不断巩固产能、采用自动化技术并与专业的合约研发生产机构（CDMO）合作，生产能力正日益成为竞争优势的重要支柱。监管定位以及与监管机构的积极沟通对于制定核准途径至关重要，尤其对于新型联合治疗和细胞疗法产品而言更是如此。此外，能够建立清晰的卫生经济学论点并及早与价值评估机构接洽的企业，更有可能获得医保报销并广泛应用。最终，竞争成功不仅取决于单一领域的优势，更取决于科学、生产、监管策略和医保沟通等方面的整合执行。

产业领导者提出切实可行的策略建议，以加速临床开发、增强生产韧性并确保患者公平获得治疗。

产业领导者应采取一系列优先策略行动，将科学进步与永续的病患用药途径连结起来。首先，各机构应透过在发现阶段早期就纳入製程开发，并检验可扩展的、品质源自于设计（QbD）的生产方法，使临床开发与可生产性保持一致。这将降低下游风险，并实现更可预测的监管互动。其次，相关人员应投资加强供应链韧性，具体措施包括供应商多元化、评估替代来源以及探索区域製造伙伴关係，以减轻地缘政治和关税相关干扰的影响。

第三，企业应儘早与支付者、医疗服务提供者和病患权益组织合作，共同製定包含真实世界治疗结果和可行支付模式的价值验证框架。第四，与技术提供者、诊断开发商和临床网路建立策略联盟，可以加快临床应用速度并扩大患者群体。第五，企业应优先考虑资料基础设施和互操作系统，以收集长期治疗结果和安全性讯号。这将有助于医保报销谈判，并为产品的迭代改进提供资讯。最后，企业应促进细胞疗法生产、监管事务和病患服务领域的人才培养，以确保组织能力与商业性目标保持同步。综上所述，这些建议为将科学突破转化为临床和商业性可行的治疗方法提供了切实可行的蓝图。

采用严谨的混合方法调查方法，包括一手访谈、临床资料库审查、监管分析和真实世界证据综合。

本调查方法采用混合方法，将质性专家访谈与临床註册资料、监管文件和科学文献的量化分析结合。主要研究包括与临床研究人员、生产企业高管、监管专家、支付方代表和患者权益倡导团体进行结构化咨询，以揭示实际应用中的挑战和推动技术应用的因素。次要研究则包括同行评审期刊、临床试验註册数据、监管指导文件、专利申请和公开信息，以检验趋势并进行结果的三角验证。

我们的分析方法包括对访谈结果进行主题综合分析、对监管路径进行比较分析以及绘製生产和供应连结口图。我们基于真实世界证据的分析重点在于治疗模式、取得障碍以及核准后安全性监测，前提是能够取得公开资料。在整个过程中，我们专注于透明地记录资料来源，谨慎解读可能存在偏差的资料集，并在专家支援下反覆验证检验，以提高结论的稳健性和实际应用价值。

对研究结果、策略意义和优先行动进行关键性综合分析，这些内容支撑着免疫疗法创新和可及性的未来发展轨迹。

总之，免疫疗法在科学和实践层面持续发展，需要相关人员将技术可能性与实际执行结合，才能真正造福患者。从精密的细胞工程和模组化製造到先进的疫苗和溶瘤病毒平台，科学创新正在拓展治疗选择，但要将其转化为常规治疗，则需要稳健的生产製造、数据驱动的报销策略，以及与区域基础设施和法规结构的协调一致。关税和地缘政治因素带来的成本压力，使得供应链多角化和在地化工作更加紧迫，凸显了战略远见的重要性。

随着该领域的不断发展，整合跨职能能力的机构将更易取得成功：将早期研发与生产可行性相结合，与支付方和医疗服务提供方合作以展现价值，建立伙伴关係以加速商业化，并投资数据系统以记录长期疗效。扩大患者群体的可及性不仅需要科学的努力，还需要营运、策略和协作。现在就采取行动加强这些方面的经营团队和临床领导者，将更有能力将免疫疗法的创新转化为切实有效的、公平的患者照护改善。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 快速应用靶向固态肿瘤肿瘤抗原的双特异性抗体
  • 拓展CAR-T疗法的应用范围：从骨髓恶性肿瘤到固态肿瘤
  • 引入免疫查核点抑制剂生物相似药，以实现新兴市场的可负担性
  • 开发能够促进T细胞浸润抗药性肿瘤的肿瘤微环境调节剂
  • 结合基因测序和人工智慧驱动的表位预测的个人化新抗原疫苗平台
  • 引入将溶瘤病毒与PD-1和CTLA-4抑制剂结合的联合治疗
  • 扩大同种异体现成天然灭活细胞产品的生产规模，简化生产流程
  • 新一代IL-2和IL-15细胞激素疗法安全性得到提升，其监管核准已加快。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：免疫治疗方法药物市场

  • 过继性细胞疗法
    • CAR-T疗法
    • NK细胞疗法
    • Tcr-T疗法
  • 癌症疫苗
    • 树突细胞疫苗
    • DNA疫苗
    • 胜肽疫苗
  • 查核点抑制剂
    • CTLA-4抑制剂
    • PD-1抑制剂
    • PD-L1抑制剂
  • 细胞激素
    • 集落刺激因子
    • 干扰素
    • 白细胞介素
  • 溶瘤病毒疗法
    • 基于腺病毒的
    • 疱疹病毒
    • 基于呼肠孤病毒

第九章：以适应症分類的免疫疗法药物市场

  • 血癌
    • 急性淋巴性白血病
    • 急性骨髓性白血病
    • 慢性淋巴性白血病
    • 淋巴瘤
  • 乳癌
    • 荷尔蒙受体阳性
    • 三重否定
  • 肺癌
    • 非小细胞肺癌
    • 小细胞肺癌
  • 黑色素瘤
    • 皮肤黑色素瘤
    • 葡萄膜黑色素瘤

第十章：按给药途径分類的免疫疗法市场

  • 瘤内给药
  • 静脉注射
  • 皮下注射

第十一章 以最终用户分類的免疫疗法药物市场

  • 医院
  • 肿瘤诊所
  • 专业中心

第十二章：免疫疗法药物市场依作用机制划分

  • 主动免疫疗法
    • 癌症疫苗
    • 溶瘤病毒疗法
  • 联合治疗
  • 被动免疫疗法
    • 过继性细胞疗法
    • 查核点抑制剂
    • 单株抗体

第十三章：各地区免疫疗法药物市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 按组别分類的免疫疗法药物市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国免疫疗法药物市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Merck & Co., Inc.
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche Ltd
    • AstraZeneca PLC
    • Novartis AG
    • Johnson & Johnson
    • Gilead Sciences, Inc.
    • Pfizer Inc.
    • Sanofi SA
    • Amgen Inc.
Product Code: MRR-521BAA36EBB6

The Immunotherapy Drugs Market is projected to grow by USD 513.82 billion at a CAGR of 12.73% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 196.96 billion
Estimated Year [2025] USD 222.59 billion
Forecast Year [2032] USD 513.82 billion
CAGR (%) 12.73%

This report opens with a concise framing of the contemporary immunotherapy landscape, clarifying the scope, objectives, and analytical approach taken to examine scientific advances, clinical evolution, regulatory developments, and commercial dynamics. It establishes the lenses through which subsequent analysis is presented, including clinical efficacy trends, manufacturing technology shifts, supply chain considerations, regulatory touchpoints, and stakeholder adoption drivers. By setting these parameters early, the narrative guides readers through interconnected themes that inform strategic decisions across research, clinical deployment, manufacturing scale-up, and market access.

Methodologically, the introduction explains the integration of primary expert interviews, clinical database reviews, regulatory documentation, patent analysis, and real-world evidence to build a coherent evidence base. It also outlines assumptions on data triangulation and the criteria used to evaluate technological maturity and adoption readiness. In doing so, the introduction positions the report as a pragmatic tool for decision-makers seeking to align scientific opportunity with operational capability and policy realities.

Transformative shifts reshaping immunotherapy research, manufacturing, commercialization and patient access that redefine clinical paradigms and investor priorities

Recent years have witnessed transformative shifts that are reshaping research priorities, commercialization pathways, and the delivery of immunotherapies to patients. Advances in precision cell engineering, such as next-generation receptor designs and allogeneic platforms, are enabling broader therapeutic concepts and the potential for off-the-shelf products. Concurrently, breakthroughs in vaccine platforms, oncolytic vectors, and immune modulators are being combined in multi-modal regimens, changing how clinical development strategies are designed and how regulatory engagement is approached. These scientific shifts are complemented by operational changes: modular manufacturing, single-use technologies, and distributed production models are redefining capacity planning and cost structures.

Moreover, financing models and investor sentiment have evolved from an emphasis on early discovery to validation of scalable manufacturing and durable clinical benefit, prompting companies to form strategic alliances and adapt go-to-market strategies. Patient access considerations are also shifting as health systems grapple with the integration of complex therapies into standard care pathways and as payers seek outcomes-linked approaches. Taken together, these developments redefine where value is created along the immunotherapy lifecycle and require stakeholders to rethink clinical design, supply chain resilience, reimbursement strategy, and long-term commercialization planning.

Cumulative implications of United States tariffs enacted in 2025 for immunotherapy supply chains, manufacturing, clinical trials, and patient access

The cumulative effect of United States tariff measures enacted in 2025 introduces a complex set of pressures across immunotherapy supply chains, manufacturing economics, and clinical operations. Tariff-related cost increases on imported reagents, specialized consumables, cell processing equipment, and certain biologic intermediates create direct operational headwinds for manufacturers and contract development and manufacturing organizations. Since many components of advanced therapy manufacturing remain globally sourced, these added costs can prompt strategic shifts including re-evaluation of supplier contracts, increased vertical integration, and accelerated localization efforts to mitigate exposure. In turn, manufacturing footprint decisions will increasingly weigh geopolitical risk alongside cost and regulatory considerations.

Beyond manufacturing, tariffs influence the economics of clinical trial operations by raising the cost of imported kits, cold-chain logistics, and outsourced laboratory services, which can extend timelines when sponsors seek alternate sources or requalify suppliers. Payers and health systems may also encounter upstream cost pressures that affect procurement strategies and adoption pathways for high-cost therapies. In response, industry stakeholders are likely to prioritize resilient sourcing strategies, diversify supplier bases, invest in domestic capacity where feasible, and engage proactively with procurement and policy stakeholders to clarify exemptions or mitigation mechanisms. Ultimately, while tariffs do not alter the scientific promise of immunotherapies, they reconfigure operational priorities and necessitate tactical adjustments across manufacturing, clinical, and commercial functions.

Actionable segmentation insights on therapy modalities, indication cohorts, administration routes, end users, and mechanisms for clinical and commercial planning

A nuanced understanding of segmentation is essential to align development strategies with clinical needs and commercial pathways. When considering therapy type, the landscape encompasses Adoptive Cell Therapy, Cancer Vaccines, Checkpoint Inhibitors, Cytokines, and Oncolytic Virus Therapy. Within Adoptive Cell Therapy, attention must be paid to subcategories such as CAR-T therapy, NK cell therapy, and TCR-T therapy because each presents distinct manufacturing, regulatory, and delivery challenges. Cancer Vaccines span dendritic cell vaccines, DNA vaccines, and peptide vaccines, which differ in antigen selection, adjuvant needs, and administration logistics. Checkpoint Inhibitors include CTLA-4 inhibitors, PD-1 inhibitors, and PD-L1 inhibitors, each with unique efficacy and toxicity profiles that shape combination strategies. Cytokine approaches, including colony stimulating factors, interferons, and interleukins, continue to play roles as modulators of immune response and as components of combination regimens. Oncolytic Virus Therapy, covering adenovirus-based, herpesvirus-based, and reovirus-based platforms, presents specific considerations around vector design, manufacturing containment, and immune profiling.

From an indication perspective, segmentation across blood cancers, breast cancer, lung cancer, and melanoma reveals divergent clinical pathways and adoption dynamics. Blood cancer subtypes such as acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, and lymphoma each demand tailored cell therapy and immunomodulatory approaches. Breast cancer segmentation into hormone receptor positive and triple negative categories reflects distinct biomarker-driven approaches and combination needs. Lung cancer differentiation between non-small cell and small cell disease affects target selection and trial design, while melanoma contexts such as cutaneous and uveal melanoma diverge in immune responsiveness. Route of administration considerations-intratumoral, intravenous, and subcutaneous-directly influence supply chain requirements, clinical infrastructure, and patient-centered care models. End users including hospitals, oncology clinics, and specialized centers will adopt therapies at different paces depending on capacity, clinician expertise, and reimbursement mechanisms. Finally, mechanisms of action framed as active immunotherapy, combination therapies, and passive immunotherapy are central to strategic prioritization: active approaches such as cancer vaccines and oncolytic virus therapy focus on inducing endogenous responses, whereas passive strategies like adoptive cell therapy, checkpoint inhibitors, and monoclonal antibodies rely on exogenous effector delivery or inhibition of inhibitory pathways. Collectively, these segmentation lenses inform prioritized development pathways, clinical trial design, and tailored commercialization strategies that reflect both scientific nuance and healthcare delivery realities.

Regional insights on adoption dynamics, infrastructure readiness, regulatory landscapes, and market access considerations across major global regions

Regional dynamics shape adoption trajectories, infrastructure readiness, regulatory engagement, and market access approaches across the globe. In the Americas, advanced therapy accelerators are visible in centers of excellence that combine academic leadership, manufacturing know-how, and payer engagement. These ecosystems support rapid clinical translation but also highlight the need for pragmatic strategies to integrate high-complexity therapies into routine care pathways and to negotiate value-based arrangements with payers.

In Europe, Middle East & Africa, regulatory harmonization efforts, national reimbursement frameworks, and diverse healthcare delivery systems create a spectrum of adoption environments. Capacity building for cell and gene therapy manufacturing and on-site clinical expertise varies widely, prompting tailored market entry strategies, regional manufacturing partnerships, and adaptive pricing approaches. In Asia-Pacific, rapid investment in biotechnology, growing clinical trial activity, and expanding domestic manufacturing capabilities are driving significant local innovation, even as regulatory pathways mature. Across all regions, infrastructure readiness-including GMP-compliant facilities, cold-chain logistics, and specialized clinical centers-remains a decisive factor in the pace of adoption, and stakeholders must align regional strategies with local regulatory and reimbursement realities to optimize patient access.

Competitive company insights examining pipeline composition, strategic alliances, manufacturing capabilities, regulatory positioning and commercialization pathways

Competitive dynamics in the immunotherapy space are characterized by a diverse mix of established pharmaceutical companies, biotechnology innovators, specialized contract manufacturers, and academic consortia. Companies with differentiated platforms that combine proprietary biology with scalable manufacturing advantage are positioned to lead, while organizations that invest in robust clinical evidence generation and real-world outcome measurement build long-term credibility with payers and clinicians. Strategic alliances, licensing deals, and targeted acquisitions remain central instruments for accelerating access to complementary capabilities such as vector production, cell processing automation, and companion diagnostics.

Manufacturing capability is an increasingly visible axis of competitive differentiation as leaders secure capacity, adopt automation, and form partnerships with specialized contract development and manufacturing organizations. Regulatory positioning and proactive engagement with authorities to shape approval pathways, especially for novel combination regimens and cell-based products, are critical. Moreover, companies that develop clear health economics narratives and engage early with value-assessment bodies enhance their prospects for reimbursement and broader adoption. Ultimately, competitive success will hinge on integrated execution across science, manufacturing, regulatory strategy, and payer engagement rather than on single-domain strength alone.

Practical and actionable strategic recommendations for industry leaders to accelerate clinical development, manufacturing resilience, and equitable patient access

Industry leaders should adopt a prioritized set of strategic actions to translate scientific progress into sustainable patient access. First, organizations must align clinical development with manufacturability by embedding process development earlier in discovery phases and by validating scalable, quality-by-design manufacturing approaches. This reduces downstream risk and enables more predictable regulatory interactions. Second, stakeholders should invest in supply chain resilience by diversifying suppliers, qualifying alternate sources, and exploring regional manufacturing partnerships to mitigate geopolitical or tariff-related disruptions.

Third, firms should engage payers, providers, and patient advocacy groups early to co-develop value demonstration frameworks that incorporate real-world outcomes and feasible payment models. Fourth, forging strategic alliances with technology providers, diagnostics developers, and clinical networks can accelerate time-to-clinic and broaden access. Fifth, companies should prioritize data infrastructure and interoperable systems to capture long-term outcomes and safety signals, which supports reimbursement negotiations and informs iterative product improvement. Finally, leaders must cultivate workforce capabilities in cell therapy manufacturing, regulatory affairs, and patient services to ensure that organizational capacity matches commercial ambition. Together, these recommendations create a practical roadmap for converting scientific breakthroughs into clinically and commercially viable therapies.

Rigorous mixed-methods research methodology integrating primary interviews, clinical database review, regulatory analysis, and real-world evidence synthesis

The research methodology employs a mixed-methods approach that integrates qualitative expert interviews with quantitative review of clinical registries, regulatory filings, and scientific literature. Primary research included structured consultations with clinical investigators, manufacturing leaders, regulatory specialists, payer representatives, and patient advocates to surface real-world challenges and adoption drivers. Secondary sources encompassed peer-reviewed journals, clinical trial registries, regulatory guidance documents, patent filings, and public disclosures to validate trends and triangulate insights.

Analytic techniques included thematic synthesis of interview findings, comparative analysis of regulatory pathways, and mapping of manufacturing and supply chain touchpoints. Real-world evidence analyses focused on treatment patterns, utilization barriers, and post-approval safety monitoring where publicly available data permitted. Throughout, emphasis was placed on transparent documentation of data provenance, conservative interpretation of datasets prone to bias, and iterative validation of conclusions with domain experts to enhance robustness and practical relevance.

Conclusive synthesis of findings, strategic significance, and priority actions underscoring the future trajectory of immunotherapy innovation and access

In conclusion, immunotherapy continues to advance across scientific and operational dimensions, and stakeholders must synthesize technological promise with pragmatic execution to realize patient impact. Scientific innovations-ranging from refined cell engineering and modular manufacturing to sophisticated vaccine and oncolytic platforms-are expanding therapeutic options, yet their translation into routine care depends on resilient manufacturing, data-driven reimbursement strategies, and regional alignment with infrastructure and regulatory frameworks. Tariff-driven cost pressures and geopolitical considerations add urgency to supply chain diversification and localization efforts, underscoring the need for strategic foresight.

As the field evolves, success will favor organizations that integrate cross-functional capabilities: aligning early development with manufacturing feasibility, engaging payers and providers to demonstrate value, building partnerships to accelerate commercialization, and investing in data systems that capture long-term outcomes. The pathway to broader patient access is not solely scientific; it is operational, strategic, and collaborative. Executives and clinical leaders who act now to strengthen these dimensions will be best positioned to translate immunotherapy innovation into meaningful, equitable improvements in patient care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid adoption of bispecific antibodies targeting dual tumor antigens in solid tumors
  • 5.2. Expansion of CAR-T therapies beyond hematologic malignancies into solid tumor indications
  • 5.3. Integration of immune checkpoint inhibitor biosimilars to improve affordability across emerging markets
  • 5.4. Development of tumor microenvironment modulators to enhance T-cell infiltration in resistant tumors
  • 5.5. Personalized neoantigen vaccine platforms combining genomic sequencing with AI-driven epitope prediction
  • 5.6. Implementation of combination therapies integrating oncolytic viruses with PD-1 and CTLA-4 inhibitors
  • 5.7. Growth of allogeneic off-the-shelf natural killer cell products to streamline manufacturing timelines
  • 5.8. Regulatory approvals accelerating for next-generation IL-2 and IL-15 cytokine therapies with improved safety profiles

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Immunotherapy Drugs Market, by Therapy Type

  • 8.1. Adoptive Cell Therapy
    • 8.1.1. Car-T Therapy
    • 8.1.2. Nk Cell Therapy
    • 8.1.3. Tcr-T Therapy
  • 8.2. Cancer Vaccines
    • 8.2.1. Dendritic Cell Vaccines
    • 8.2.2. Dna Vaccines
    • 8.2.3. Peptide Vaccines
  • 8.3. Checkpoint Inhibitors
    • 8.3.1. Ctla-4 Inhibitors
    • 8.3.2. Pd-1 Inhibitors
    • 8.3.3. Pd-L1 Inhibitors
  • 8.4. Cytokines
    • 8.4.1. Colony Stimulating Factors
    • 8.4.2. Interferons
    • 8.4.3. Interleukins
  • 8.5. Oncolytic Virus Therapy
    • 8.5.1. Adenovirus Based
    • 8.5.2. Herpesvirus Based
    • 8.5.3. Reovirus Based

9. Immunotherapy Drugs Market, by Indication

  • 9.1. Blood Cancer
    • 9.1.1. Acute Lymphoblastic Leukemia
    • 9.1.2. Acute Myeloid Leukemia
    • 9.1.3. Chronic Lymphocytic Leukemia
    • 9.1.4. Lymphoma
  • 9.2. Breast Cancer
    • 9.2.1. Hormone Receptor Positive
    • 9.2.2. Triple Negative
  • 9.3. Lung Cancer
    • 9.3.1. NonSmallCell Lung Cancer
    • 9.3.2. SmallCell Lung Cancer
  • 9.4. Melanoma
    • 9.4.1. Cutaneous Melanoma
    • 9.4.2. Uveal Melanoma

10. Immunotherapy Drugs Market, by Route Of Administration

  • 10.1. Intratumoral
  • 10.2. Intravenous
  • 10.3. Subcutaneous

11. Immunotherapy Drugs Market, by End User

  • 11.1. Hospitals
  • 11.2. Oncology Clinics
  • 11.3. Specialized Centers

12. Immunotherapy Drugs Market, by Mechanism Of Action

  • 12.1. Active Immunotherapy
    • 12.1.1. Cancer Vaccines
    • 12.1.2. Oncolytic Virus Therapy
  • 12.2. Combination Therapies
  • 12.3. Passive Immunotherapy
    • 12.3.1. Adoptive Cell Therapy
    • 12.3.2. Checkpoint Inhibitors
    • 12.3.3. Monoclonal Antibodies

13. Immunotherapy Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Immunotherapy Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Immunotherapy Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Merck & Co., Inc.
    • 16.3.2. Bristol-Myers Squibb Company
    • 16.3.3. F. Hoffmann-La Roche Ltd
    • 16.3.4. AstraZeneca PLC
    • 16.3.5. Novartis AG
    • 16.3.6. Johnson & Johnson
    • 16.3.7. Gilead Sciences, Inc.
    • 16.3.8. Pfizer Inc.
    • 16.3.9. Sanofi S.A.
    • 16.3.10. Amgen Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. IMMUNOTHERAPY DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. IMMUNOTHERAPY DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. IMMUNOTHERAPY DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CAR-T THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CAR-T THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CAR-T THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CAR-T THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY NK CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY NK CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY NK CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY NK CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY NK CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY NK CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY TCR-T THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY TCR-T THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY TCR-T THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY TCR-T THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY TCR-T THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY TCR-T THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY DENDRITIC CELL VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY DENDRITIC CELL VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY DENDRITIC CELL VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY DENDRITIC CELL VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY DENDRITIC CELL VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY DENDRITIC CELL VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY DNA VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY DNA VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY DNA VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY DNA VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY DNA VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY DNA VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PEPTIDE VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PEPTIDE VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PEPTIDE VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PEPTIDE VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PEPTIDE VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PEPTIDE VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY COLONY STIMULATING FACTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY COLONY STIMULATING FACTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY COLONY STIMULATING FACTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY COLONY STIMULATING FACTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY COLONY STIMULATING FACTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY COLONY STIMULATING FACTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTERFERONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTERFERONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTERFERONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTERFERONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTERFERONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTERLEUKINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTERLEUKINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTERLEUKINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTERLEUKINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTERLEUKINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTERLEUKINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADENOVIRUS BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADENOVIRUS BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADENOVIRUS BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADENOVIRUS BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADENOVIRUS BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADENOVIRUS BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY HERPESVIRUS BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY HERPESVIRUS BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY HERPESVIRUS BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY HERPESVIRUS BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY HERPESVIRUS BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY HERPESVIRUS BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY REOVIRUS BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY REOVIRUS BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY REOVIRUS BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY REOVIRUS BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY REOVIRUS BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY REOVIRUS BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY LYMPHOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY LYMPHOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY TRIPLE NEGATIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY TRIPLE NEGATIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY TRIPLE NEGATIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY TRIPLE NEGATIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY TRIPLE NEGATIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY TRIPLE NEGATIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY NONSMALLCELL LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY NONSMALLCELL LUNG CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY NONSMALLCELL LUNG CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY NONSMALLCELL LUNG CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY NONSMALLCELL LUNG CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY NONSMALLCELL LUNG CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY SMALLCELL LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY SMALLCELL LUNG CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY SMALLCELL LUNG CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY SMALLCELL LUNG CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY SMALLCELL LUNG CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY SMALLCELL LUNG CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CUTANEOUS MELANOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CUTANEOUS MELANOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CUTANEOUS MELANOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CUTANEOUS MELANOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CUTANEOUS MELANOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CUTANEOUS MELANOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY UVEAL MELANOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY UVEAL MELANOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY UVEAL MELANOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY UVEAL MELANOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY UVEAL MELANOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY UVEAL MELANOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTRATUMORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTRATUMORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTRATUMORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTRATUMORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTRATUMORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTRATUMORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY SPECIALIZED CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY SPECIALIZED CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY SPECIALIZED CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY SPECIALIZED CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY SPECIALIZED CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY SPECIALIZED CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY COMBINATION THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY COMBINATION THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY COMBINATION THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY COMBINATION THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 301. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 302. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 303. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 304. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 305. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 306. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 307. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 308. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 309. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 310. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 311. GLOBAL IMMUNOTHERAP